A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Ocellaris Pharma, Inc.
Blueprint Medicines Corporation
Actym Therapeutics, Inc.
Incyte Corporation
Elevation Oncology
Mayo Clinic
NantCell, Inc.
Pfizer
pharmaand GmbH
MacroGenics
Seagen Inc.
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cambridge University Hospitals NHS Foundation Trust
Tocagen Inc.
CureOne
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
GOG Foundation